Clinical Trial Update: DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating DRP-104, a glutamine antagonist, in combination with durvalumab for advanced fibrolamellar hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrolamellar Hepatocellular Carcinoma

Drugs mentioned

• DRP-104
• Durvalumab (durvalumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Fibrolamellar Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: RECRUITING